CClinicalTrials.gg
Sign In
CompletedNCT03493282Updated Sep 7, 2023Results posted

Effect of CT1812 Treatment on Brain Synaptic Density

A Phase 1/2 interventional study of Active Treatment- CT1812 100 mg and Active Treatment- CT1812 300 mg in Alzheimer Disease, sponsored by Cognition Therapeutics. Completed at 1 site in United States. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-09-07.

Sponsored by Cognition Therapeutics · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Study summary

Study to Evaluate the Safety and Tolerability of Oral CT1812 in Subjects with Mild to Moderate Alzheimer's Disease.

Read the detailed description

This is a single-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease to evaluate the safety and tolerability of oral CT1812, administered for up 180 days for the Primary study and another 180 days for the double-blind extension study.

Each participant and caregiver participated in a screening period of up to 60 days, followed by the primary double-blind treatment period of 24 weeks (169 days +/-2) followed by an optional double-blind extension treatment period of another 24 weeks (337 days +/-2).

02

Conditions studied

  • Alzheimer Disease

Browse trials for

03

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Participants may be included in the study only if they meet all of the following criteria:

    1. Men, and women of non-childbearing potential, 50-85 years of age inclusively, with a diagnosis of mild to moderate Alzheimer's disease according to the 2011 NIA-AA criteria and at least a 6 month decline in cognitive function documented in the medical record.

      1. Non-childbearing potential for women is defined as postmenopausal [last natural menses greater than 24 months; in women under age 55, menopausal status will be documented with serum follicle stimulating hormone (FSH) test] or undergone a documented bilateral tubal ligation or hysterectomy.
      2. Male participants who are sexually active with a woman of child-bearing potential must agree to use condoms during the trial and for 3 months after last dose unless the woman is using an acceptable means of birth control. Acceptable forms of birth control include abstinence, birth control pills, or any double combination of: intrauterine device (IUD), male or female condom, diaphragm, sponge, and cervical cap.
    2. Neuroimaging (MRI) obtained during screening consistent with the clinical diagnosis of Alzheimer's disease and without findings of significant exclusionary abnormalities (see exclusion criteria, number 3).
    3. MMSE 18-26 inclusive
    4. A positive amyloid (Pittsburgh imaging compound B) scan at screening, or history of a positive amyloid scan prior to study entry, or prior lumbar puncture with a CSF Abeta concentration consistent with Alzheimer's disease.
    5. Formal education of eight or more years.
    6. Must have a caregiver who sees them at least 10 hours per week, oversees the administration of study drug, and is willing and able to oversee administration of study medication and participate in all clinic visits and some study assessments. The caregiver must provide written informed consent to participate in the study.
    7. Living at home or in the community (assisted living acceptable)
    8. Able to swallow CT1812 capsules.
    9. Stable pharmacological treatment of any other chronic conditions for at least 30 days prior to screening.
    10. Capable of providing either written informed consent or oral assent to the study procedures and for use of protected health information [Health Insurance Portability and Accountability Act (HIPAA) Authorization, if applicable]. If the Participant can provide only assent, their legally authorized representative also must provide written informed consent. Written informed consent also shall be obtained from the responsible caregiver. All consent processes must be undertaken in the presence of a witness and prior to any study procedures.
    11. Must consent to apolipoprotein E (ApoE) genotyping.
    12. Generally healthy with mobility (ambulatory or ambulatory-aided, i.e., walker or cane), vision and hearing (hearing aid permissible) sufficient for compliance with testing procedures.
    13. Able to complete all screening evaluations.

Exclusion criteria

Exclusion Criteria:

  • Participants will be excluded from the study if any of the following conditions apply:

    1. Hospitalization or change of chronic concomitant medication within one month prior to screening.
    2. Patients living in a continuous care nursing facility
    3. Screening MRI of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage or infarct > 1 cm3, >3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g. abscess or brain tumor such as meningioma).

    4. MRI incompatible implants and other contraindications for MRI, such as pacemaker, artificial joints, non-removable body piercings, etc. Additionally, participants who meet the following imaging exclusion criteria will not be included in this study:

      1. Claustrophobia that will result in significant anxiety and difficulty lying still for brain imaging (MRI or PET).
      2. Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the participant to exceed the yearly dose limits for healthy volunteers.
      3. History of IV drug use that would prevent venous access for PET tracer injection.
      4. Severe motor problems that prevent the participant from lying still for brain imaging.
      5. Severe chronic pain (e.g., as the result of rheumatoid arthritis) that would prevent them from lying still during brain imaging.

    5. Clinical or laboratory findings consistent with:

      1. Other primary degenerative dementia, (dementia with Lewy bodies, fronto-temporal dementia, Huntington's disease, Jacob-Creutzfeld Disease, Down's syndrome, etc.)
      2. Other neurodegenerative condition (Parkinson's disease, amyotrophic lateral sclerosis, etc.)
      3. Seizure disorder
      4. Other infectious, metabolic or systemic diseases affecting the central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, other laboratory values) etc.)
    6. A current DSM-V diagnosis of active major depression, schizophrenia or bipolar disorder. Patients with depressive symptoms successfully managed by a stable dose of an antidepressant are allowed entry.

    7. Clinically significant, advanced or unstable disease that may interfere with outcome evaluations, such as:

      1. Chronic liver disease, liver function test abnormalities or other signs of hepatic insufficiency (ALT, AST, total bilirubin > 1.5 x ULN)
      2. Respiratory insufficiency
      3. Renal insufficiency eGFR \< 45 mL/min based on the CKD-EPI formula (https://www.questdiagnostics.com/home/physicians/egfr-calculator)Heart disease (myocardial infarction, unstable angina, heart failure, cardiomyopathy within six months before screening)
      4. Bradycardia (\<45/min.) or tachycardia (>100/min.)
      5. Poorly managed hypertension (systolic >160 mm Hg and/or diastolic >95 mm Hg) or hypotension (systolic \<90 mm Hg and/or diastolic \<60 mm Hg)
      6. Uncontrolled diabetes defined by HbA1c >8
    8. History of cancer within 3 years of screening with the exception of fully excised non-melanoma skin cancers or non-metastatic prostate cancer that has been stable for at least 6 months.
    9. Seropositive for human immunodeficiency virus (HIV).
    10. History of acute/chronic hepatitis B or C and/or carriers of hepatitis B (seropositive for Hepatitis B surface antigen [HbsAg] or anti-Hepatitis C [HCV] antibody).

    11. Clinically significant abnormalities in screening laboratory tests, including:

      1. hematocrit less than 33% for males and less than 30% for females
      2. absolute neutrophil cell count of 1200/uL (with the exception of a documented history of a chronic benign neutropenia), or platelet cell count of \< 120,000/uL
      3. INR >1.4 or other coagulopathy, confirmed by repeat.
    12. Disability that may prevent the patient from completing all study requirements (e.g. blindness, deafness, severe language difficulty, etc.)
    13. Women who are fertile and of childbearing potential.
    14. Within 4 weeks of screening visit or during the course of the study, concurrent treatment with antipsychotic agents (except risperidone ≤1.5 mg/day, quetiapine ≤100 mg/day, olanzapine ≤5 mg/day, and aripiprazole ≤10 mg/day), antiepileptics (except gabapentin and pregabalin for nonseizure indications), centrally active anti-hypertensive drugs (e.g., clonidine, l-methyl dopa, guanidine, guanfacine, etc.), opiate analgesics, systemic corticosteroids, psychostimulants, antiparkinsonian medications (except for non-parkinsonian indications) and mood stabilizers (e.g., valproate, lithium), sedatives and anxiolytics with the exception that use of short- to medium-acting benzodiazepines for treatment of insomnia is permitted, however, use of sedatives or hypnotics should be avoided for 8 hours before administration of cognitive tests.
    15. Any disorder that could interfere with the absorption, distribution, metabolism or excretion of drugs (e.g. small bowel disease, Crohn's disease, celiac disease, or liver disease.)
    16. Nootropic drugs except stable AD meds (acetylcholinesterase inhibitors and memantine
    17. Suspected or known drug or alcohol abuse, i.e. more than approximately 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine) per day indicated by elevated MCV significantly above normal value at screening.
    18. Suspected or known allergy to any components of the study treatments.
    19. Enrollment in another investigational study or intake of investigational drug within the previous 30 days or five half-lives of the investigational drug, whichever is longer.
    20. Previous exposure to anti Aβ vaccines
    21. Exposure to passive immunotherapies for AD (e.g. monoclonal antibodies) or BACE inhibitors within the previous 180 days.
    22. Contraindication to undergoing an LP including, but not limited to: inability to tolerate an appropriately flexed position for the time necessary to perform an LP; international normalized ratio (INR) > 1.4 or other coagulopathy; platelet count of \< 120,000/μL; infection at the desired lumbar puncture site; taking anti-coagulant medication within 90 days of screening (Note: low dose aspirin is permitted); degenerative arthritis of the lumbar spine; suspected non-communicating hydrocephalus or intracranial mass; prior history of spinal mass or trauma.
    23. Use of NSAIDs more than 2 days in within any 7-day period. Each incidence of use must be recorded in the source and CRF.
    24. Any condition, which in the opinion of the investigator or the sponsor makes the patient unsuitable for inclusion.
04

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Active comparator
    300 mg

    High Dose CT1812

    Drug: Active Treatment- CT1812 300 mg

  • Active comparator
    100 mg

    Low Dose CT1812

    Drug: Active Treatment- CT1812 100 mg

  • Placebo comparator
    Placebo

    Matching Placebo

    Drug: Placebo

Interventions

  • DrugActive Treatment- CT1812 100 mg

    CT1812

  • DrugActive Treatment- CT1812 300 mg

    CT1812

  • DrugPlacebo

    Matching Placebo

05

What researchers measure

Primary outcomes

  1. Number of TEAEs, Related TEAEs, SAEs, and Related SAEs

    Number of subjects reported with AEs and the number of AEs reported following administration of the IP summarized by treatment and grouped according to system organ class and preferred term, using descriptive statistics. Summaries of AEs were also presented by severity and by relationship to investigational product. In these summaries, subjects were counted only once per MedDRA term, for the AE of highest severity or least favorable relationship. Summaries were also presented of SAEs and of AEs leading to study withdrawal.

    Time frame: Up to 12 months

Secondary outcomes

  1. Change From Baseline in the Imaging of [11C] UCB-J PET Distribution Volume Ratio (DVR)

    The Distribution Volume Ratio (DVR) was used to determine the correlations with the cognitive and functional endpoints. For 11C UCB J, the imaging outcome measure was DVR as produced by the Simplified Reference Tissue Model (SRTM2) using dynamic scan data from 0 to 60 min and the whole cerebellum as a reference region. Change from baseline is calculated as the observed value minus the baseline value. A negative change from baseline indicates the progression of disease.

    Time frame: Day 169

  2. Change From Baseline in the Imaging of [18F]FDG PET SUV Ratio (SUVR)

    For 18F FDG, the primary imaging outcome measure was the SUVR from 60-90 min post injection using whole cerebellum as a reference region. For SUVR, a composite region was determined, including: prefrontal, lateral temporal, posterior cingulate/precuneus, anterior cingulate, lateral parietal, medial temporal, and lateral occipital regions. Change from baseline is calculated as the observed value minus the baseline value. A negative change from baseline indicates the progression of the disease.

    Time frame: Day 169

  3. Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI)

    A composite region of AD affected brain regions was determined, including prefrontal, lateral temporal, posterior cingulate/precuneus, anterior cingulate, lateral parietal, medial temporal, and lateral occipital regions. Baseline is defined as the last measurement taken before the first dose of study drug. Change from baseline is calculated as the observed value minus the baseline value. A negative change from baseline indicates the progression of disease.

    Time frame: Day 169

  4. Change From Baseline in the Imaging of Functional MRI - Intrinsic Connectivity Contrast (ICC)

    For resting state functional MRI, the outcome was ICC. With this approach a map of the total connectivity of each voxel to all other voxels was computed. For ICC, a composite region of AD affected brain regions was determined, including prefrontal, lateral temporal, posterior cingulate/precuneus, anterior cingulate, lateral parietal, medial temporal, and lateral occipital regions. Change from baseline is calculated as the observed value minus the baseline value. A negative change from baseline indicates the progression of disease.

    Time frame: Day 169

  5. Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers

    Change from baseline in CSF Aβ 40, CSF Aβ 42, CSF tau, CSF phospho-tau, CSF neurogranin (NRGN), CSF synaptotagmin, CSF(SNAP25), and CSF neurofilament light (NFL). Change from baseline is calculated as the observed value minus the baseline value.

    Time frame: Day 169

  6. Change From Baseline ADAS-Cog11 (Alzheimer's Disease Assessment Scale - Cognition Subscale)

    The ADAS-Cog11 total score = the sum of all 11 individual items (word recall \[10\]; commands \[5\]; constructional praxis \[5\]; naming objects and fingers \[5\]; ideational praxis \[5\]; orientation \[8\]; word recognition \[12\]; remembering test instructions \[5\]; spoken language \[5\]; word finding \[5\]; and comprehension of spoken language \[5\]). The score range for ADAS-cog 11 is 0-70 where a higher score is worse performance. The ADAS-cog methodology is to sum scores for subscales. The results were calculated using the average change from baseline. Baseline is defined as the last measurement taken before the first dose of study drug is administered. Change is calculated as the observed value minus the baseline value. A negative change from baseline indicates improvement.

    Time frame: Day 169

  7. Change From Baseline ADAS-Cog13 (Alzheimer's Disease Assessment Scale - Cognition Subscale)

    The ADAS-Cog13 total score includes all of the items in the ADAS-Cog11 and the delayed word recall and the number cancellation. For the ADAS-cog 13 the range is 0-85 (score range for Delayed Word Recall \[DWR\] score is 0-10 and for Number Cancellation \[NC\] is 0-5, thus the score is ADAS-cog 11\[0-70\] plus the scores for DWR and NC). A higher score indicates worse performance. The ADAS-cog methodology is to sum scores for subscales. The results were calculated using the average change from baseline. Baseline is defined as the last measurement taken before the first dose of study drug. Change is calculated as the observed value minus the baseline value. A negative change from baseline indicates improvement in cognitive function.

    Time frame: Day 169

  8. Change From Baseline ADAS-Cog14 (Alzheimer's Disease Assessment Scale - Cognition Subscale)

    The ADAS-Cog14 total score includes all of the items in the ADAS-Cog13 \[0-85\] and the maze item which has a score range of 0-5. Thus, the total score for the ADAS-cog 14 is 0-90 where again a higher score is worst performance. The ADAS-cog methodology is to sum scores for subscales. The results were calculated using the average change from baseline. Baseline is defined as the last measurement taken before the first dose of study drug is administered. Change is calculated as the observed value minus the baseline value. A negative change from baseline indicates improvement in cognitive function.

    Time frame: Day 169

  9. Change From Baseline in ADCS-Activities of Daily Living (ADCS-ADL)

    The ADCS-ADL is a 23-item informant-administered assessment of functional impairment in terms of activities of daily living. Informants respond to 23 questions about the subject's involvement and level of performance across items representing daily living. The questions range from basic to instrumental activities of daily living. Each item is rated from the highest level of independent performance to complete loss. The total score range is from 0-78 with lower scores indicating greater functional impairment. A positive change from baseline indicates improvement in function. The results were calculated using the average change from baseline. Higher scores mean better outcome. Negative mean indicates worsening of function. Positive mean indicates improvement of function.

    Time frame: Day 169

  10. Change From Baseline in Mini Mental State Exam (MMSE)

    The MMSE assesses several aspects of memory and cognitive functioning including orientation, attention, concentration, comprehension, recall, and praxis. The total possible score is 30, with high scores indicating less impairment. Change from baseline is calculated as the observed value minus the baseline value. A positive change from baseline indicates improvement in cognition.

    Time frame: Day 169

  11. Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)

    Scores were on a scale of 0 through 3, with 0=no dementia, 0.5=questionable dementia, 1=mild dementia, 2=moderate dementia, and 3=severe dementia. Cognitive and functional abilities that were assessed include Memory; Orientation; Judgment and Problem Solving; Community Affairs; Home and Hobbies; and Personal Care. Memory was considered as the primary driver for scoring and the other categories were secondary. The change from baseline in the CDR-SB total score was analyzed using the mixed model for repeated measures (MMRM). Change from baseline is calculated as the observed value minus the baseline value. Higher scores mean worsening of disease.

    Time frame: Day 169

  12. Change From Baseline in Alzheimer's Disease Clinical Study - Clinician Global Impression of Change (ADCS-CGIC)

    The scale consists of a format with which a clinician may address clinically relevant overall change, including 15 areas under the domains of cognition, behavior, and social and daily functioning. For ADCS-CGIC, the individual data listing presented the original score on the seven-point scale. In addition, the seven-point score was collapsed to 3 groups, combining scores 1-3 to "Improved", 4 to "No change", and 5-7 to "Worsening". Lower scores indicate improvement.

    Time frame: Day 169

  13. Change From Baseline in the Cognitive Composite

    The Cognitive composite included: 1. 6 ADAS-Cog items: word recall, orientation, delayed word recall, word recognition, number cancellation, and maze 2. 4 Neuropsychological Test Battery (NTB) items: Trail Making Test (TMT) A, Trail Making Test (TMT) B, Category Fluency Test (CFT), Digit span. Each individual z-score was calculated by first computing the baseline mean and standard deviation at baseline for all subjects within each individual component. The z-scores were then derived for each subject and timepoint by subtracting the corresponding baseline mean from the observed value and then dividing by the standard deviation at baseline. The sign of the z-score for the following components was reversed when deriving the Composite scores: Word recall, Orientation, Delayed Word Recall, Word Recognition, Maze, TMT A, TMT B. Z-score = 0 represents the population at baseline Positive Z-score = indicates improvement Negative Z-score= indicates worsening

    Time frame: Day169

  14. Change From Baseline in the Memory Composite

    The memory composite includes 4 ADAS-COG (Alzheimer's Disease Assessment Scale - cognition subscale) items: word recall, orientation, delayed word recall, word recognition. The Memory composite score will be a composite z-score average similar to the Cognitive Composite score but will only be derived using the average of the ADAS-Cog Word Recall, Orientation, Delayed Word Recall, and Word Recognition items. If a subject is missing any of the four items at a timepoint, this composite score will not be derived. The score was calculated using z-scores of the items cited above where: Z-score = 0 represents the population at baseline. Positive Z-score = indicates improvement Negative Z-score= indicates worsening

    Time frame: Day169

  15. Change From Baseline in Attention Composite

    The Attention composite score included: 1. 1 ADAS-COG (Alzheimer's Disease Assessment Scale -cognition subscale) item: Number Cancellation 2. 1 NTB item: Trail Making Test (TMT) A The Attention composite score will be a composite z-score average derived using the average of the Number Cancellation, Maze item from ADAS-Cog 14, and TMT A items. If a subject missed either of the three items at a timepoint, this composite score was derived. The score was calculated using z-scores of the items cited above where: Z-score = 0 represents the population at baseline. Positive Z-score = indicates improvement Negative Z-score= indicates worsening

    Time frame: Day 169

  16. Change From Baseline in the Executive Composite

    The Executive composite included 1. 0 ADAS-COG (Alzheimer's Disease Assessment Scale - cognition subscale) items 2. 3 NTB (Neuropsychological Test Battery) items: CFT (Category Fluency Test), Digit Span, and Trail Making Test (TMT) B The Executive function composite score will be a composite z-score average derived using the average of the CFT Category Fluency Test), Digit Span, and TMT B items. If a subject is missing any of the three items at a timepoint, this composite score will not be derived. The score was calculated using z-scores of the items cited above where: Z-score = 0 represents the population at baseline. Positive Z-score = indicates improvement Negative Z-score= indicates worsening

    Time frame: Day 169

06

Results

Posted Mar 1, 2023

Participant flow

Location Type: Medical Clinic

Primary Double-blind Study (180 Days)
Participant flow — Primary Double-blind Study (180 Days)
Milestone300 mg100 mgPlacebo
Started887
Completed566
Not completed321
Withdrew: Adverse event221
Withdrew: Subject moved100
Double-blind Extension Study (180 Days)
Participant flow — Double-blind Extension Study (180 Days)
Milestone300 mg100 mgPlacebo
Started364
Completed364
Not completed000

Outcome measures

PrimaryNumber of TEAEs, Related TEAEs, SAEs, and Related SAEs

Number of subjects reported with AEs and the number of AEs reported following administration of the IP summarized by treatment and grouped according to system organ class and preferred term, using descriptive statistics. Summaries of AEs were also presented by severity and by relationship to investigational product. In these summaries, subjects were counted only once per MedDRA term, for the AE of highest severity or least favorable relationship. Summaries were also presented of SAEs and of AEs leading to study withdrawal.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
Participants300 mg100 mgPlaceboAll Subjects
All TEAEs78621
Mild TEAEs64414
Moderate TEAEs1214
Severe TEAEs0213
Related TEAEs43411
TEAEs Leading to Treatment Discontinuation2215
SAEs0314
Related SAEs0000
SecondaryChange From Baseline in the Imaging of [11C] UCB-J PET Distribution Volume Ratio (DVR)

The Distribution Volume Ratio (DVR) was used to determine the correlations with the cognitive and functional endpoints. For 11C UCB J, the imaging outcome measure was DVR as produced by the Simplified Reference Tissue Model (SRTM2) using dynamic scan data from 0 to 60 min and the whole cerebellum as a reference region. Change from baseline is calculated as the observed value minus the baseline value. A negative change from baseline indicates the progression of disease.

Time frame:
Day 169
Reported as:
Mean · ratio
Change From Baseline in the Imaging of [11C] UCB-J PET Distribution Volume Ratio (DVR)
ratio300 mg100 mgPlacebo
Change From Baseline in the Imaging of [11C] UCB-J PET Distribution Volume Ratio (DVR)-0.043 ± 0.020-0.019 ± 0.0200.000 ± 0.020
SecondaryChange From Baseline in the Imaging of [18F]FDG PET SUV Ratio (SUVR)

For 18F FDG, the primary imaging outcome measure was the SUVR from 60-90 min post injection using whole cerebellum as a reference region. For SUVR, a composite region was determined, including: prefrontal, lateral temporal, posterior cingulate/precuneus, anterior cingulate, lateral parietal, medial temporal, and lateral occipital regions. Change from baseline is calculated as the observed value minus the baseline value. A negative change from baseline indicates the progression of the disease.

Time frame:
Day 169
Reported as:
Mean · ratio
Change From Baseline in the Imaging of [18F]FDG PET SUV Ratio (SUVR)
ratio300 mg100 mgPlacebo
Change From Baseline in the Imaging of [18F]FDG PET SUV Ratio (SUVR)-0.084 ± 0.017-0.044 ± 0.017-0.053 ± 0.017
SecondaryChange From Baseline in Volumetric Magnetic Resonance Imaging (MRI)

A composite region of AD affected brain regions was determined, including prefrontal, lateral temporal, posterior cingulate/precuneus, anterior cingulate, lateral parietal, medial temporal, and lateral occipital regions. Baseline is defined as the last measurement taken before the first dose of study drug. Change from baseline is calculated as the observed value minus the baseline value. A negative change from baseline indicates the progression of disease.

Time frame:
Day 169
Reported as:
Mean · cm^3
Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI)
cm^3300 mg100 mgPlacebo
Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI)-6.34 ± 3.49-5.59 ± 3.51-13.85 ± 3.39
SecondaryChange From Baseline in the Imaging of Functional MRI - Intrinsic Connectivity Contrast (ICC)

For resting state functional MRI, the outcome was ICC. With this approach a map of the total connectivity of each voxel to all other voxels was computed. For ICC, a composite region of AD affected brain regions was determined, including prefrontal, lateral temporal, posterior cingulate/precuneus, anterior cingulate, lateral parietal, medial temporal, and lateral occipital regions. Change from baseline is calculated as the observed value minus the baseline value. A negative change from baseline indicates the progression of disease.

Time frame:
Day 169
Reported as:
Mean · ratio
Change From Baseline in the Imaging of Functional MRI - Intrinsic Connectivity Contrast (ICC)
ratio300 mg100 mgPlacebo
Change From Baseline in the Imaging of Functional MRI - Intrinsic Connectivity Contrast (ICC)0.005 ± 0.006-0.008 ± 0.006-0.006 ± 0.007
SecondaryChange From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers

Change from baseline in CSF Aβ 40, CSF Aβ 42, CSF tau, CSF phospho-tau, CSF neurogranin (NRGN), CSF synaptotagmin, CSF(SNAP25), and CSF neurofilament light (NFL). Change from baseline is calculated as the observed value minus the baseline value.

Time frame:
Day 169
Reported as:
Mean · pg/ml
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers
pg/ml300 mg100 mgPlacebo
Aβ 40 (pg/ml)-594.0 ± 381.57517.70 ± 445.24222.25 ± 397.27
Aβ 42 (pg/ml)-32.96 ± 17.5511.62 ± 21.88-13.90 ± 19.66
Tau (pg/ml)-84.08 ± 111.96121.22 ± 131.9636.74 ± 120.70
Phospho-tau (pg/ml)-7.71 ± 12.605.80 ± 14.91-4.67 ± 13.59
NRGN (pg/ml)-26.79 ± 16.5014.96 ± 19.61-5.54 ± 17.77
Synaptotagmin (pg/ml)0.88 ± 2.246.37 ± 2.640.68 ± 2.44
SNAP-25 (pg/ml)-3.15 ± 1.540.74 ± 1.831.36 ± 1.66
NFL (pg/ml)210.77 ± 149.24265.74 ± 176.40-24.02 ± 164.56
SecondaryChange From Baseline ADAS-Cog11 (Alzheimer's Disease Assessment Scale - Cognition Subscale)

The ADAS-Cog11 total score = the sum of all 11 individual items (word recall \[10\]; commands \[5\]; constructional praxis \[5\]; naming objects and fingers \[5\]; ideational praxis \[5\]; orientation \[8\]; word recognition \[12\]; remembering test instructions \[5\]; spoken language \[5\]; word finding \[5\]; and comprehension of spoken language \[5\]). The score range for ADAS-cog 11 is 0-70 where a higher score is worse performance. The ADAS-cog methodology is to sum scores for subscales. The results were calculated using the average change from baseline. Baseline is defined as the last measurement taken before the first dose of study drug is administered. Change is calculated as the observed value minus the baseline value. A negative change from baseline indicates improvement.

Time frame:
Day 169
Reported as:
Mean · score on a scale
Change From Baseline ADAS-Cog11 (Alzheimer's Disease Assessment Scale - Cognition Subscale)
score on a scale300 mg100 mgPlacebo
Change From Baseline ADAS-Cog11 (Alzheimer's Disease Assessment Scale - Cognition Subscale)1.78 ± 2.1011.28 ± 2.0911.37 ± 2.144
SecondaryChange From Baseline ADAS-Cog13 (Alzheimer's Disease Assessment Scale - Cognition Subscale)

The ADAS-Cog13 total score includes all of the items in the ADAS-Cog11 and the delayed word recall and the number cancellation. For the ADAS-cog 13 the range is 0-85 (score range for Delayed Word Recall \[DWR\] score is 0-10 and for Number Cancellation \[NC\] is 0-5, thus the score is ADAS-cog 11\[0-70\] plus the scores for DWR and NC). A higher score indicates worse performance. The ADAS-cog methodology is to sum scores for subscales. The results were calculated using the average change from baseline. Baseline is defined as the last measurement taken before the first dose of study drug. Change is calculated as the observed value minus the baseline value. A negative change from baseline indicates improvement in cognitive function.

Time frame:
Day 169
Reported as:
Mean · score on a scale
Change From Baseline ADAS-Cog13 (Alzheimer's Disease Assessment Scale - Cognition Subscale)
score on a scale300 mg100 mgPlacebo
Change From Baseline ADAS-Cog13 (Alzheimer's Disease Assessment Scale - Cognition Subscale)2.62 ± 2.1571.73 ± 2.1461.02 ± 2.178
SecondaryChange From Baseline ADAS-Cog14 (Alzheimer's Disease Assessment Scale - Cognition Subscale)

The ADAS-Cog14 total score includes all of the items in the ADAS-Cog13 \[0-85\] and the maze item which has a score range of 0-5. Thus, the total score for the ADAS-cog 14 is 0-90 where again a higher score is worst performance. The ADAS-cog methodology is to sum scores for subscales. The results were calculated using the average change from baseline. Baseline is defined as the last measurement taken before the first dose of study drug is administered. Change is calculated as the observed value minus the baseline value. A negative change from baseline indicates improvement in cognitive function.

Time frame:
Day 169
Reported as:
Mean · score on a scale
Change From Baseline ADAS-Cog14 (Alzheimer's Disease Assessment Scale - Cognition Subscale)
score on a scale300 mg100 mgPlacebo
Change From Baseline ADAS-Cog14 (Alzheimer's Disease Assessment Scale - Cognition Subscale)1.25 ± 2.5441.42 ± 2.2451.65 ± 2.290
SecondaryChange From Baseline in ADCS-Activities of Daily Living (ADCS-ADL)

The ADCS-ADL is a 23-item informant-administered assessment of functional impairment in terms of activities of daily living. Informants respond to 23 questions about the subject's involvement and level of performance across items representing daily living. The questions range from basic to instrumental activities of daily living. Each item is rated from the highest level of independent performance to complete loss. The total score range is from 0-78 with lower scores indicating greater functional impairment. A positive change from baseline indicates improvement in function. The results were calculated using the average change from baseline. Higher scores mean better outcome. Negative mean indicates worsening of function. Positive mean indicates improvement of function.

Time frame:
Day 169
Reported as:
Mean · score on a scale
Change From Baseline in ADCS-Activities of Daily Living (ADCS-ADL)
score on a scale300 mg100 mgPlacebo
Change From Baseline in ADCS-Activities of Daily Living (ADCS-ADL)-3.16 ± 1.646-0.31 ± 1.5222.21 ± 1.641
SecondaryChange From Baseline in Mini Mental State Exam (MMSE)

The MMSE assesses several aspects of memory and cognitive functioning including orientation, attention, concentration, comprehension, recall, and praxis. The total possible score is 30, with high scores indicating less impairment. Change from baseline is calculated as the observed value minus the baseline value. A positive change from baseline indicates improvement in cognition.

Time frame:
Day 169
Reported as:
Mean · score on a scale
Change From Baseline in Mini Mental State Exam (MMSE)
score on a scale300 mg100 mgPlacebo
Change From Baseline in Mini Mental State Exam (MMSE)-2.92 ± 1.540-1.26 ± 1.448-0.74 ± 1.547
SecondaryChange From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)

Scores were on a scale of 0 through 3, with 0=no dementia, 0.5=questionable dementia, 1=mild dementia, 2=moderate dementia, and 3=severe dementia. Cognitive and functional abilities that were assessed include Memory; Orientation; Judgment and Problem Solving; Community Affairs; Home and Hobbies; and Personal Care. Memory was considered as the primary driver for scoring and the other categories were secondary. The change from baseline in the CDR-SB total score was analyzed using the mixed model for repeated measures (MMRM). Change from baseline is calculated as the observed value minus the baseline value. Higher scores mean worsening of disease.

Time frame:
Day 169
Reported as:
Mean · score on a scale
Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)
score on a scale300 mg100 mgPlacebo
Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)0.72 ± 0.4210.39 ± 0.3990.17 ± 0.409
SecondaryChange From Baseline in Alzheimer's Disease Clinical Study - Clinician Global Impression of Change (ADCS-CGIC)

The scale consists of a format with which a clinician may address clinically relevant overall change, including 15 areas under the domains of cognition, behavior, and social and daily functioning. For ADCS-CGIC, the individual data listing presented the original score on the seven-point scale. In addition, the seven-point score was collapsed to 3 groups, combining scores 1-3 to "Improved", 4 to "No change", and 5-7 to "Worsening". Lower scores indicate improvement.

Time frame:
Day 169
Reported as:
Mean · score on a scale
Change From Baseline in Alzheimer's Disease Clinical Study - Clinician Global Impression of Change (ADCS-CGIC)
score on a scale300 mg100 mgPlacebo
Change From Baseline in Alzheimer's Disease Clinical Study - Clinician Global Impression of Change (ADCS-CGIC)4.80 ± 0.2794.50 ± 0.2574.68 ± 0.257
SecondaryChange From Baseline in the Cognitive Composite

The Cognitive composite included: 1. 6 ADAS-Cog items: word recall, orientation, delayed word recall, word recognition, number cancellation, and maze 2. 4 Neuropsychological Test Battery (NTB) items: Trail Making Test (TMT) A, Trail Making Test (TMT) B, Category Fluency Test (CFT), Digit span. Each individual z-score was calculated by first computing the baseline mean and standard deviation at baseline for all subjects within each individual component. The z-scores were then derived for each subject and timepoint by subtracting the corresponding baseline mean from the observed value and then dividing by the standard deviation at baseline. The sign of the z-score for the following components was reversed when deriving the Composite scores: Word recall, Orientation, Delayed Word Recall, Word Recognition, Maze, TMT A, TMT B. Z-score = 0 represents the population at baseline Positive Z-score = indicates improvement Negative Z-score= indicates worsening

Time frame:
Day169
Reported as:
Mean · Z-Score
Change From Baseline in the Cognitive Composite
Z-Score300 mg100 mgPlacebo
Change From Baseline in the Cognitive Composite-0.33 ± 0.109-0.11 ± 0.102-0.10 ± 0.109
SecondaryChange From Baseline in the Memory Composite

The memory composite includes 4 ADAS-COG (Alzheimer's Disease Assessment Scale - cognition subscale) items: word recall, orientation, delayed word recall, word recognition. The Memory composite score will be a composite z-score average similar to the Cognitive Composite score but will only be derived using the average of the ADAS-Cog Word Recall, Orientation, Delayed Word Recall, and Word Recognition items. If a subject is missing any of the four items at a timepoint, this composite score will not be derived. The score was calculated using z-scores of the items cited above where: Z-score = 0 represents the population at baseline. Positive Z-score = indicates improvement Negative Z-score= indicates worsening

Time frame:
Day169
Reported as:
Mean · Z-score
Change From Baseline in the Memory Composite
Z-score300 mg100 mgPlacebo
Change From Baseline in the Memory Composite-0.49 ± 0.201-0.18 ± 0.201-0.14 ± 0.198
SecondaryChange From Baseline in Attention Composite

The Attention composite score included: 1. 1 ADAS-COG (Alzheimer's Disease Assessment Scale -cognition subscale) item: Number Cancellation 2. 1 NTB item: Trail Making Test (TMT) A The Attention composite score will be a composite z-score average derived using the average of the Number Cancellation, Maze item from ADAS-Cog 14, and TMT A items. If a subject missed either of the three items at a timepoint, this composite score was derived. The score was calculated using z-scores of the items cited above where: Z-score = 0 represents the population at baseline. Positive Z-score = indicates improvement Negative Z-score= indicates worsening

Time frame:
Day 169
Reported as:
Mean · Z-score
Change From Baseline in Attention Composite
Z-score300 mg100 mgPlacebo
Change From Baseline in Attention Composite-0.01 ± 0.1580.15 ± 0.132-0.13 ± 0.139
SecondaryChange From Baseline in the Executive Composite

The Executive composite included 1. 0 ADAS-COG (Alzheimer's Disease Assessment Scale - cognition subscale) items 2. 3 NTB (Neuropsychological Test Battery) items: CFT (Category Fluency Test), Digit Span, and Trail Making Test (TMT) B The Executive function composite score will be a composite z-score average derived using the average of the CFT Category Fluency Test), Digit Span, and TMT B items. If a subject is missing any of the three items at a timepoint, this composite score will not be derived. The score was calculated using z-scores of the items cited above where: Z-score = 0 represents the population at baseline. Positive Z-score = indicates improvement Negative Z-score= indicates worsening

Time frame:
Day 169
Reported as:
Mean · Z-score
Change From Baseline in the Executive Composite
Z-score300 mg100 mgPlacebo
Change From Baseline in the Executive Composite-0.35 ± 0.3660.66 ± 0.364-0.03 ± 0.256

Adverse events

Collected over Up to 12 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
300 mg0/8 (0%)0/8 (0%)7/8 (87.5%)
100 mg0/8 (0%)3/8 (37.5%)8/8 (100%)
Placebo0/7 (0%)1/7 (14.3%)6/7 (85.7%)
Most frequent serious events
Most frequent serious events
Event300 mg100 mgPlacebo
EncephalitisInfections and infestations0/80/81/7
UreterolithiasisRenal and urinary disorders0/81/80/7
Thalamic InfarctionNervous system disorders0/81/80/7
Psychotic disorderPsychiatric disorders0/81/80/7
SeizureNervous system disorders0/81/80/7
Most frequent other events
Showing 10 of 51
Most frequent other events
Event300 mg100 mgPlacebo
HeadacheNervous system disorders3/82/82/7
Upper respiratory tract infectionInfections and infestations0/82/80/7
Urinary tract infectionInfections and infestations0/82/80/7
VomitingGastrointestinal disorders0/82/81/7
Liver function test increasedInvestigations2/80/80/7
EncephalitisInfections and infestations0/80/81/7
Cerebral microhaemorrhageNervous system disorders0/80/81/7
DiarrhoeaGastrointestinal disorders0/80/81/7
Swelling faceSkin and subcutaneous tissue disorders0/80/81/7
ArthralgiaMusculoskeletal and connective tissue disorders0/80/81/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)300 mg100 mgPlaceboTotal
Mean69.6 ± 10.968.0 ± 9.372.6 ± 5.870.0 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)300 mg100 mgPlaceboTotal
Female44311
Male44412
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)300 mg100 mgPlaceboTotal
Hispanic or Latino0000
Not Hispanic or Latino88723
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)300 mg100 mgPlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0011
White88622
More than one race0000
Unknown or Not Reported0000
Weight
Weight(kg)300 mg100 mgPlaceboTotal
Mean76.2 ± 16.985.6 ± 5.074.8 ± 9.279.0 ± 12.1
Height
Height(cm)300 mg100 mgPlaceboTotal
Mean170.3 ± 9.9171.4 ± 12.5172.1 ± 12.1171.2 ± 11.0
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)300 mg100 mgPlaceboTotal
Mean26.3 ± 5.729.5 ± 4.125.2 ± 1.827.1 ± 4.5
07

Study locations

1 site
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
08

References and documents

Study documents

  • Study protocol · Feb 3, 2021
  • Statistical analysis plan · Mar 11, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03493282
Lead sponsor
Cognition Therapeutics
Collaborators
National Institute on Aging (NIA)
Responsible party
Sponsor
First posted
Apr 10, 2018
Start date
Mar 28, 2018
Primary completion
Oct 16, 2020
Completion
Oct 16, 2020
Results posted
Mar 1, 2023
Last update
Sep 7, 2023

Study contacts

Christopher van Dyck, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Alzheimer Disease→

Other studies from this sponsor

Cognition Therapeutics

Start the discussion